Ghent University and MDxHealth Collaborate to Establish a Center in Pharmaco (Epi)genomics
(Thomson Reuters ONE) -
IRVINE, CA, and LIEGE, BELGIUM - November 30, 2012 - MDxHealth SA (NYSE
Euronext: MDXH), a leading molecular diagnostic company that develops and
commercializes epigenetic tests to support cancer treatment, today announced
that it has joined forces with the Ghent University to establish NXTGNT, a new
Center in Pharmaco (Epi)genomics.
The mission of the Center is to accelerate innovation in personalized medicine
by using advanced technology, knowledge and expertise in (epi)genetics. The
Center will bring together scientific expertise from disease centered basic
researchers, corresponding clinical validation teams, bioinformaticians, and
cutting edge (epi)genomic technology focused on the discovery of effective
individualized epigenetic-based diagnostic and personalized therapeutic
products.
As a result of several years of productive collaboration between the Laboratory
of Bioinformatics and Computational Genomics (BIOBIX), NXTGNT (UGent genome
analysis facility), the Biomarked valorization consortium teams and MDxHealth,
the new Center is located at Ghent University within the laboratory of
Pharmaceutical Biotechnology. The facility will house MDxHealth's research team
and lab equipment for development of epigenetic tests together with the Ghent
University team for (epi)genetic sequencing. The facility works in close
collaboration with the Laboratory of Bioinformatics and Computational Genomics,
located at the Faculty of BioEngeneering, providing extensive expertise in
epigenetic characterization and computing and visualization of (epi)genomic
datasets. The Center is fully operational as off December 1, 2012.
"The creation of NXTGNT as a Center in Pharmaco (Epi)genomics is welcome
advancement in the field of epigenetics and personalized medicine. There is a
history of successful collaboration between MDxHealth and the University of
Ghent, where much of the early epigenetics sequencing work on our biomarkers was
conducted," said Dr. Jan Groen CEO of MDxHealth. "As more drugs are being
developed alongside companion tests, there is a growing need for novel
technologies, biomarkers and assays. We believe our experience in successfully
developing personalized cancer epigenetic tests combined with the sequencing,
bioinformatics and methylome analysis expertise contained in the new Center will
prove extremely attractive to the pharmaceutical industry."
"The partners in NXTGNT and the University of Ghent have an established track
record in biomarker research. Performing research towards technological
advances, identification and validation of novel and more accurate biomarkers
for risk stratification and prediction of therapy and our expertise in data-
analysis and the development of new bioinformatic tools are an asset in this
collaboration," Said Prof. Dieter Deforce from the University of Ghent, one of
the NXTGNT partners. "By collaborating with MDxHealth we will ensure that
results from our research in the collaboration field will be brought to the
market in a more efficient way. Bringing the right partners together with the
necessary contacts in the pharmaceutical industry will allow us to further
advance in the field of personalized medicine."
About MDxHealth
MDxHealth is a molecular diagnostics company that develops and commercializes
advanced epigenetic tests for cancer assessment and the personalized treatment
of patients. The company's first commercial product, the ConfirmMDx(TM) for
Prostate Cancer test, has been shown to help distinguish patients who have a
true-negative biopsy from those who may have occult cancer. MDxHealth helps to
address a large and growing unmet medical need for better cancer diagnosis and
treatment information. The company has a proprietary platform and a strong
epigenetic product pipeline focused on the development of products for brain and
lung cancers. The company is based in Irvine, California with a European
headquarters in Liege, Belgium. For more information visit MDxHealth website at
www.mdxhealth.com.
For more information:
Dr. Jan Groen, CEO Mike Sinclair
MDxHealth Halsin Partners
US: +1 949 812 6979 UK: +44 20 7318 2955
BE: +32 4 364 20 70 Cell: +44 7968 022075
info(at)mdxhealth.com msinclair(at)halsin.com
This press release contains forward-looking statements and estimates with
respect to the anticipated future performance of MDxHealth and the market in
which it operates. Such statements and estimates are based on assumptions and
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable but may not prove to be correct. Actual events are
difficult to predict, may depend upon factors that are beyond the company's
control, and may turn out to be materially different. MDxHealth expressly
disclaims any obligation to update any such forward-looking statements in this
release to reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such statement is
based unless required by law or regulation.
UGent collaboration ENG:
http://hugin.info/137314/R/1661248/538157.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MdxHealth via Thomson Reuters ONE
[HUG#1661248]
Unternehmensinformation / Kurzprofil:
Datum: 30.11.2012 - 08:02 Uhr
Sprache: Deutsch
News-ID 208432
Anzahl Zeichen: 6482
contact information:
Town:
Liège
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 249 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Ghent University and MDxHealth Collaborate to Establish a Center in Pharmaco (Epi)genomics"
steht unter der journalistisch-redaktionellen Verantwortung von
MdxHealth (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
